FimH confers mannose-targeting ability to Bacillus Calmette-Guerin for improved immunotherapy in bladder cancer
Background Bladder cancer is a common disease worldwide with most patients presenting with the non-muscle-invasive form (NMIBC) at initial diagnosis. Postoperational intravesical instillation of BCG is carried out for patients with high-risk disease to reduce tumor recurrence and progression to musc...
Saved in:
| Main Authors: | Yang Zhang, Chao Yan, Ru Jia, Qiang Lv, Fan Huo, Qiang Cao, Qiju Huang, Zhu A Wang, Dan Theodorescu, Pengchao Li |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2022-03-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/10/3/e003939.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety profiles of intravesical Bacillus Calmette-Guerin in bladder cancer
by: Yun Peng, et al.
Published: (2024-12-01) -
Pneumonitis secondary to intravesical Bacillus-Calmette-Guérin (BCG) immunotherapy
by: Komeil Alattar, MBBS, PGCert, et al.
Published: (2025-09-01) -
Saudi urologists’ treatment pattern for high-risk Bacillus Calmette–Guérin naïve and Bacillus Calmette–Guérin unresponsive nonmuscle invasive bladder cancer
by: Mohammad Alghafees, et al.
Published: (2025-01-01) -
Systemic granulomatous reaction secondary to treatment of bladder cancer with Bacillus Calmette-Guerin
by: Caterina Giovanna Valentini, et al.
Published: (2012-01-01) -
Systemic granulomatous reaction secondary to treatment of bladder cancer with Bacillus Calmette-Guerin
by: Caterina Giovanna Valentini, et al.
Published: (2012-06-01)